UroGen Pharma Settles Jelmyto Patent Litigation with Teva, Securing Exclusivity Until 2030
URGN has more than doubled off its 52-week low of $3.605.
Summary
UroGen Pharma has settled its patent litigation with Teva Pharmaceuticals regarding Jelmyto, granting Teva a license to sell a generic version starting September 15, 2030.
Key Events · Legal and Risk Events · URGN
-
Patent Litigation Resolved
UroGen Pharma entered into a settlement and license agreement with Teva Pharmaceuticals, resolving patent litigation related to its drug Jelmyto®.
-
Generic Entry Date Established
The agreement grants Teva a non-exclusive license to sell a generic version of Jelmyto starting September 15, 2030, subject to FDA approval.
-
Legal Uncertainty Removed
All ongoing patent litigation between the parties regarding Jelmyto patents will be terminated, providing long-term clarity on market exclusivity.
Analysis · URGN · Life Sciences
This settlement resolves significant patent litigation concerning Jelmyto, a key product for UroGen Pharma. By establishing a generic entry date of September 15, 2030, the company gains long-term clarity on its revenue stream for this drug and removes the financial and operational uncertainty associated with ongoing legal battles. This de-risks a core asset and provides a clear runway for continued sales.
At the time of this filing, URGN was trading at $26.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $3.61 to $32.37. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.